Sensitivity of Fite-Faraco versus auramine-rhodamine in mycobacterial infection - 10/10/20
Doi : 10.1016/j.jaad.2020.07.002
Alan N. Snyder, BS a, ⁎ 
, Heather O'Connor, MD b, John G. Plante, BS a, Latiffa J. Smith, BS a, Dirk M. Elston, MD a
, Heather O'Connor, MD b, John G. Plante, BS a, Latiffa J. Smith, BS a, Dirk M. Elston, MD a a Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina
b Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina
∗Correspondence to: Alan Snyder, BS, 176 Broad St, Apartment B, Charleston, SC 29401176 Broad StApartment BCharlestonSC29401
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Reviewed and approved by Health Sciences South Carolina IRB (approval no. 93499). |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 5
P. 1526-1527 - novembre 2020 Retour au numéro
Article précédent
- The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
- Maha N. Syed, Daniel B. Shin, Marilyn T. Wan, Kevin L. Winthrop, Joel M. Gelfand
- Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration
- Shari R. Lipner, Yu Wang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?